Phase 1b Trial of YTX-7739 Shows Safety, Early Potential in Patients

Phase 1b Trial of YTX-7739 Shows Safety, Early Potential in Patients

311946

Phase 1b Trial of YTX-7739 Shows Safety, Early Potential in Patients

Yumanity Therapeutics announced that its investigational therapy, YTX-7739, worked to safely inhibit stearoyl-CoA desaturase — an enzyme thought to play a role in the alpha-synuclein-derived toxicity seen in Parkinson’s — in a Phase 1b clinical trial in people with mild-to-moderate disease. Data from this trial, conduced in the Netherlands, is expected to help inform the design of a Phase 2 trial that could start next year. “We are very encouraged by the results from this Phase 1b…

You must be logged in to read/download the full post.